Compare FBIN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBIN | ADPT |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 2011 | 2019 |
| Metric | FBIN | ADPT |
|---|---|---|
| Price | $47.98 | $28.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $49.06 | $32.57 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $4,463,200,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $10.85 |
| Revenue Next Year | N/A | $21.60 |
| P/E Ratio | $111.02 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $32.34 | $12.00 |
| 52 Week High | $64.84 | $32.21 |
| Indicator | FBIN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 53.42 |
| Support Level | $36.96 | $24.02 |
| Resistance Level | $53.86 | $29.92 |
| Average True Range (ATR) | 2.17 | 1.77 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 55.43 | 46.56 |
Fortune Brands is a US-based homebuilding products company that sells building-related products serving R&R and new construction markets. The company operates in three segments: water, outdoors, and security. Water innovation, including plumbing fixtures and faucets, accounts for around 55% of total sales and features brands such as Moen, House of Rohl, and Aqualisa. The outdoors segment includes decking, railing, and doors and makes up 30% of total sales, featuring brands such as Larson, Fiberon, and Therma-Tru. The security segment, which includes smart residential padlocks, accounts for the remaining 15% of sales and features brands such as MasterLock, SentrySafe, Yale, and AmericanLock.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.